特朗普:愿意就研发新冠病毒疫苗与中国合作
美国总统特朗普表示,愿意与中国或其他国家合作,将有效的新冠病毒疫苗带到美国。
较早时,研究人员称,由康希诺生物(06185.HK)与中国军方研究机构开发的疫苗能在大部分接种者身上产生免疫反应。而其他多间公司的疫苗亦取得类似的结果,包括美国的Moderna、德国生物科技公司BioNTech及美国药厂辉瑞等。
特朗普一直指责中国隐瞒疫情,导致美国超过14万人死亡。特朗普表示,预计在研发疫苗方面会在非常短得时间内取得好结果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.